We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients on a shorter dosing regimen in Gilead’s phase 3 remdesivir trial saw clinical improvements similar to those on the 10-day treatment schedule, the drugmaker announced Wednesday, offering hope of a COVID-19 treatment. Read More
Remdesivir should be part of the “first wave” of efforts to expedite COVID-19 treatments and vaccines, the members of Scientists to Stop COVID-19 said in a plan submitted to the White House. Read More
Challenge studies for COVID-19 vaccines are “incomprehensible” as long as there are safer alternatives, Generex CEO Joe Moscato said yesterday, responding to a letter from lawmakers last week on the subject. Read More
A New York healthcare network is studying famotidine, the active ingredient in the heartburn drug Pepcid, as a potential treatment for COVID-19. Read More
Sanofi and Regeneron have modified their clinical trial of the rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after preliminary results found no benefit in one group. Read More